Rosiglitazone: Policy Implications and Continuing Debate

As the rosiglitazone (Avandia, GlaxoSmithKline [GSK]) controversy continues, some policy implications of the whole affair, focusing on reform of the FDA, have emerged from the written testimony of Dr. Brian Strom (University of Pennsylvania School of Medicine, Philadelphia) submitted to the congressional hearing earlier this month.
TheHeart.org